Kodak Health Imaging chief Coyne refutes rumors of unit's divestitureSpeculation had centered on Johnson & Johnson saleEastman Kodak is not seeking to divest its Kodak Health Imaging business, according to Martin Coyne, president of
Speculation had centered on Johnson & Johnson sale
Eastman Kodak is not seeking to divest its Kodak Health Imaging business, according to Martin Coyne, president of the Rochester, NY, film and PACS business. Although Kodak is cutting jobs in the unit along with the rest of the company, Kodak is committed to medical imaging and has no plans to sell off the business, he said.
Coyne was responding to rumors that swept the exhibit floor during last month's Radiological Society of North America meeting. Most of the rumors claimed that Kodak would be selling off the Health Imaging business to healthcare giant Johnson & Johnson.
Like many RSNA rumors, however, this one apparently had little basis in fact.
"We are not being acquired, we are not being divested, and Kodak senior management is committed to the health business for the foreseeable future, for the long term," Coyne said.
Kodak's widely publicized restructuring effort provided fuel for the rumors to spread. Kodak in November announced that it would be cutting 10,000 jobs throughout the company in an effort to improve profitability. The moves are a response to difficulties in the company's core consumer film market, which has been losing market share to arch-rival Fuji. At the same time, Kodak's much-hyped moves into consumer digital imaging have yet to pay off. In December, Kodak announced that it would cut another 6600 jobs, taking a $1.5 billion charge in the process.
Staff reductions have been taking place throughout Kodak Health Imaging since the initial restructuring was announced in November, Coyne said. He declined to detail how many or what type of jobs were being eliminated, other than to say that the division is looking at making its entire work force more efficient. Kodak's R&D efforts have not been spared scrutiny, according to Coyne.
"Our R&D has been refocused. We will do fewer projects than we previously have done, and we will do them better and faster," he said. "The reality was that, as in most companies, we tried to do too much."
The change will probably result in more partnering agreements, such as the relationship Kodak has with Applicare Medical Imaging for Windows NT workstations. The Applicare workstations have been installed as part of Kodak's implementation of a full-scale PACS at New York Hospital in New York City.
The New York Hospital sale was portrayed as a sign that Kodak had arrived on the PACS scene, but since then no new major sales have been announced. This is due to the long sales cycle of PACS, according to Coyne, which can take up to a year to complete. In any event, Kodak is working on a number of large-scale sales, and the vendor does not intend to exit the market.
"We are committed to the digital business, and we are going to grow that business. We have to," Coyne said. "If we are going to continue to be a world leader in health imaging, we've got to be the leader in analog, digital, and hybrid solutions."
Can MRI-Guided Transurethral Ultrasound Ablation Have an Impact for Localized Prostate Cancer?
December 11th 2023Follow-up MRI imaging one year after transurethral ultrasound ablation revealed approximately 50 percent decreases in prostate volume and median PSA density, according to recently presented research findings at the 2023 Society of Urologic Oncology (SUO) Annual Meeting.
What a New Mammography Study Reveals About BMI, Race, Ethnicity and Advanced Breast Cancer Risk
December 8th 2023In a new study examining population attributable risk proportions (PARPs) based on data from over three million screening mammography exams, researchers found that postmenopausal Black women had the highest BMI-related PARP and premenopausal Asian and Pacific Islander women had the highest breast density-related PARP for advanced breast cancer.
Study: Contrast-Enhanced Mammography Changes Surgical Plan in 22.5 Percent of Breast Cancer Cases
December 7th 2023Contrast-enhanced mammography detected additional lesions in 43 percent of patients and led to additional biopsies in 18.2 percent of patients, over half of whom had malignant lesions, according to a study of over 500 women presented at the recent Radiological Society of North America (RSNA) conference.
What a New Study Reveals About Adjunctive DBT and Early-Stage Invasive Breast Cancer
December 6th 2023The combination of digital breast tomosynthesis (DBT) and digital mammography had a 21.6 higher invasive breast cancer detection rate for stage 1 tumors than digital mammography alone, according to a new study involving nearly 100,000 women.